Exelixis, Inc. splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Jan 2, 2026 was Product Gross at $3.0 billion, 130% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Oct 2, 2026
|
FY 2025
Jan 2, 2026
|
FY 2024
Jan 3, 2025
|
FY 2023
Dec 29, 2023
|
FY 2022
Dec 30, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Jan 1, 2021
|
FY 2019
Jan 3, 2020
|
FY 2018
Dec 28, 2018
|
FY 2017
Dec 29, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2,497
|
2,320
|
2,169
|
1,830
|
1,611
|
1,435
|
988
|
968
|
854
|
452
|
191
|
| Product Gross |
3,226
+9.3%
share 129.2%
|
3,012
+19.6%
share 129.8%
|
2,518
+10.8%
share 116.1%
|
2,273
+16.5%
share 124.2%
|
1,951
+34.3%
share 121.1%
|
1,453
+50.9%
share 101.3%
|
963
+0.5%
share 97.5%
|
958
share 99.0%
|
—
|
—
|
—
|
| License |
242
+22.4%
share 9.7%
|
214
-38.6%
share 9.2%
|
349
+95.5%
share 16.1%
|
179
+10.2%
share 9.8%
|
162
-35.2%
share 10.1%
|
250
+49.4%
share 17.4%
|
167
+0.8%
share 16.9%
|
166
share 17.1%
|
—
|
—
|
—
|
| Cometriq |
8
-18.1%
share 0.3%
|
9
-15.4%
share 0.4%
|
11
-19.9%
share 0.5%
|
14
-45.0%
share 0.8%
|
25
+9.2%
share 1.6%
|
23
+1.5%
share 1.6%
|
23
-13.8%
share 2.3%
|
27
share 2.7%
|
—
|
—
|
—
|
| Services |
-24
-3921.0%
share -1.0%
|
-17
-269.5%
share -0.7%
|
10
-55.7%
share 0.5%
|
23
-52.5%
share 1.2%
|
48
-55.7%
share 3.0%
|
108
+36.9%
share 7.5%
|
79
+87.8%
share 8.0%
|
42
share 4.3%
|
—
|
—
|
—
|
| Product Sales Discounts And Allowances |
-947
-10.2%
share -37.9%
|
-889
-25.4%
share -38.3%
|
-709
-10.1%
share -32.7%
|
-644
-17.0%
share -35.2%
|
-550
-46.4%
share -34.1%
|
-376
-69.9%
share -26.2%
|
-221
-11.8%
share -22.4%
|
-198
share -20.4%
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- EXEL (Nasdaq)
- Fiscal year ends
- January 1
- Incorporated in
- DE
- Headquarters
- Alameda, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 939767
- Former names
- EXELIXIS INC (until Sep 12, 2012)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.